PA5-64621

antibody from Invitrogen Antibodies

Targeting: BRCA1 BRCC1, FANCS, PPP1R53, RNF53

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-64621

Provider

Invitrogen Antibodies

Product name

Phospho-BRCA1 (Ser1497) Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Phospho-BRCA1 (Ser1497) Polyclonal Antibody detects endogenous levels of BRCA1 only when phosphorylated at Ser1497.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20°C

References

Submitted references

PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.

Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y, Zhang C
Frontiers in cell and developmental biology 2021;9:719192

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of BRCA1 in UV treated 293 whole cell lysates using a Phospho-BRCA1 (Ser1497) Polyclonal Antibody (Product # PA5-64621).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 6 Treatment of Oxaliplatin inhibits HR repair pathways via blocking CDK1-BRCA1 activities in Oxaliplatin resistance cell line. (A) Verification by WB on the effects of Olaparib + Oxaliplatin, Oxaliplatin, Olaparib, AG-02432 and cisplatin on CDK1 expression and its phosphorylation, BRCA1 expression and its phosphorylation, RAD51 expression in SNU719, MKN74, and AGS Oxaliplatin resistance strains. Drug action time was 36 h. (B) Histochemical results of protein phosphorylation in gastric cancer patients. (C,D) The effects of Olaparib + Oxaliplatin and cisplatin combined with CDK1 inhibitor Olaparib on colony formation of overexpressed PARP1 and normally expressed PARP1 cell lines in SNU719, MKN74, and AGS Oxaliplatin resistance strains. Colonies were stained with crystal violet. The Student's t test was used for statistical analysis. Error bars indicate mean +- standard deviation. OXA, Oxaliplatin. OLP, Olaparib. CON, control group. CISP, cisplatin. PCDK1, CDK1 phosphorylation antibody. PBRCA1, BRCA1 phosphorylation antibody. AGSR, AGS Oxaliplatin resistance. SNU719R, SNU719 Oxaliplatin resistance. MKN74R, MKN74 Oxaliplatin resistance. * < 0.05. All experiments were repeated three times.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 7 Oxaliplatin inhibits HR repair pathways via blocking both CDK1-BRCA1. (A) Representative images of immunofluorescent CDK1 phosphorylation and BRCA1 phosphorylation staining of Olaparib + exaliplatin, Oxaliplatin, Olaparib, and blank control group in MKN74, SNU719, AGS Oxaliplatin resistance cell lines. The scale represents 20 um. Drug action time was 36 h. (B,C) Proportion of CDK1 phosphorylation and BRCA1 phosphorylation positive cells (A) , respectively. (D) Representative images of immunofluorescent phosporylation staining comparisons of Olaparib + Oxaliplatin, Oxaliplatin, Olaparib and blank control group and immunofluorescent phosphorylation staining of RAD51 and BRCA1 of MKN74, SNU719, AGS resistant strains RAD51, and BRCA1 at different time. The scale represents 2 um. (E) Statistical analysis of RAD51 + cells in (D) . The Student's t test was used for statistical analysis. Error bars indicate mean +- standard deviation. OXA, Oxaliplatin. OLP, Olaparib. CON, control group. PCDK1, CDK1 phosphorylation antibody. PBRCA1, BRCA1 phosphorylation antibody. AGSRE, AGS Oxaliplatin resistance. SNU719RE, SNU719 Oxaliplatin resistance. MKN74RE, MKN74 Oxaliplatin resistance. *< 0.05, **< 0.01, and ***< 0.001. All experiments were repeated three times.